Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Methylome analysis reveals alterations in DNA methylation in the regulatory regions of left ventricle development genes in human dilated cardiomyopathy

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE81339 | GEO | 2016/08/15

SECONDARY ACCESSION(S): PRJNA321314

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Methylome analysis reveals alterations in DNA methylation in the regulatory regions of left ventricle development genes in human dilated cardiomyopathy

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-08-15 | E-GEOD-81339 | biostudies-arrayexpress

Methylome analysis reveals alterations in DNA methylation in the regulatory regions of left ventricle development genes in human dilated cardiomyopathy (methylation)

Project description:Alterations in DNA methylation and gene expression have been implicated in the development of human dilated cardiomyopathy (DCM). In this study, we analyzed DNA methylomes (Infinium 450K HumanMethylation BeadChip) and characterize differentially methylated probes between the left and right ventricles Illumina 450K array and HT-12 v4 array for the left, right ventricles

2016-08-15 | E-GEOD-81337 | biostudies-arrayexpress

Methylome analysis reveals alterations in DNA methylation in the regulatory regions of left ventricle development genes in human dilated cardiomyopathy (mRNA)

Project description:Alterations in DNA methylation and gene expression have been implicated in the development of human dilated cardiomyopathy (DCM). In this study, we analyzed DNA methylomes (Infinium 450K HumanMethylation BeadChip) and transcriptomes (Infinium HT-12 v4) to characterize differentially methylated probes (DMPs) and differentially expressed genes (DEGs) between the left and right ventricles of human DCM. Illumina 450K array and HT-12 v4 array for the left, right ventricles

2016-08-15 | E-GEOD-81338 | biostudies-arrayexpress

Methylome analysis reveals alterations in DNA methylation in the regulatory regions of left ventricle development genes in human dilated cardiomyopathy (mRNA)

Project description:Alterations in DNA methylation and gene expression have been implicated in the development of human dilated cardiomyopathy (DCM). In this study, we analyzed DNA methylomes (Infinium 450K HumanMethylation BeadChip) and transcriptomes (Infinium HT-12 v4) to characterize differentially methylated probes (DMPs) and differentially expressed genes (DEGs) between the left and right ventricles of human DCM.

2016-08-15 | GSE81338 | GEO

Methylome analysis reveals alterations in DNA methylation in the regulatory regions of left ventricle development genes in human dilated cardiomyopathy (methylation)

2016-08-15 | GSE81337 | GEO

Methylome analysis reveals alterations in DNA methylation in the regulatory regions of left ventricle development genes in human dilated cardiomyopathy

Project description:Methylome analysis reveals alterations in DNA methylation in the regulatory regions of left ventricle development genes in human dilated cardiomyopathy

| PRJNA321314 | ENA

Transcription profiling of heart left ventricle from patients with idopathic dilated cardiomyopathy and normal controls

Project description:The mechanisms underlying the balancing of circulatory demands against changes in cellular homeostasis and cell death/survival signaling in heart muscle disease are still not fully understood. We employed the ABI high-density oligonucleotide microarrays containing 31,700 sixty-mer oligonucleotide probes (representing 27,868 individual human genes) to determine differential gene expression in idiopathic dilated cardiomyopathy (DCM) (n=5) compared to normal controls (n=4), in order to systematically characterize disease-induced alterations in gene expression that may provide a basis for deciphering such mechanisms.

2010-01-01 | E-TABM-480 | biostudies-arrayexpress

Data of methylome and transcriptome derived from human dilated cardiomyopathy.

Project description:Alterations in DNA methylation and gene expression have been implicated in the development of human dilated cardiomyopathy (DCM). Differentially methylated probes (DMPs) and differentially expressed genes (DEGs) were identified between the left ventricle (LV, a pathological locus for DCM) and the right ventricle (RV, a proxy for normal hearts). The data in this DiB are for supporting our report entitled "Methylome analysis reveals alterations in DNA methylation in the regulatory regions of left ventricle development genes in human dilated cardiomyopathy" (Bong-Seok Jo, In-Uk Koh, Jae-Bum Bae, Ho-Yeong Yu, Eun-Seok Jeon, Hae-Young Lee, Jae-Joong Kim, Murim Choi, Sun Shim Choi, 2016) [1].

| S-EPMC5035344 | biostudies-literature

Changes in molecular profiles of the left ventricle during progressive dilated cardiomyopathy linked heart failure

Project description:To investigate molecular profiles of progressive heart failure, we studied mice that lack expression of the muscle LIM protein (MLPKO). These mice showed dramatic HF progression between three and six weeks of age. We then performed gene expression profile analysis using data obtained from RNA-seq of mid wall left ventricular heart tissue from MLPKO mice and wild-type (WT) controls at three, six, and ten weeks of age (n=3 per group).

2023-06-29 | GSE225008 | GEO

Timing of Left Ventricular Remodeling in Nonischemic Dilated Cardiomyopathy.

Project description:BACKGROUND:Mineralocorticoid receptor antagonist (MRA) treatment produces beneficial left ventricular (LV) remodeling in nonischemic dilated cardiomyopathy (NIDCM). This study addressed the timing of maximal beneficial LV remodeling in NIDCM when adding MRA. MATERIALS AND METHODS:We studied 12 patients with NIDCM on stable ?-blocker and angiotensin-converting enzyme inhibitor/angiotensin receptor-blocking therapy who underwent cardiac magnetic resonance imaging before and after 6-31 months of continuous MRA therapy. RESULTS:At baseline, the LV ejection fraction (LVEF) was 24% (19-27); median [interquartile range]. The LV end-systolic volume index (LVESVI) was 63 ml (57-76) and the LV stroke volume index (LVSVI) was 19 ml (14-21), all depressed. After adding MRA to the HF regimen, the LVEF increased to 47% (42-52), with a decrease in LVESVI to 36 ml (33-45) and increase in LVSVI to 36 ml (28-39) (for each, P ?< 0?.0001). Using generalized least squares analysis, the maximal beneficial remodeling (defined by maximal increase in LVEF, the maximal decrease in LVESVI and maximal increase in LVSVI) was achieved after approximately 12-16 months of MRA treatment. CONCLUSIONS:Adding MRA to a standard medical regimen for NIDCM resulted in beneficial LV remodeling. The maximal beneficial remodeling was achieved with 12-16 months of MRA therapy. These results have implications for the timing of other advanced therapies, such as placing internal cardioverter-defibrillators.

| S-EPMC7388723 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data